CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 10 enrolled
Drug / intervention
levalbuterol +5 moredrug
Likely dose
levalbuterol 0.5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02170532
NCT02170532Phase 4Completed

Aerosolized Beta-Agonist Isomers in Asthma

Duke University·interventional·Posted Jun 23, 2014·Updated Aug 13, 2014

In Brief

A Phase 4 clinical trial evaluating levalbuterol, saline, and 4 other interventions for Asthma. Completed, enrolled 10 participants.

Detailed Summary

Dr. MacIntyre and his colleagues are studying inhaled medications in asthma. There are two new medications that have been approved by the United States Food and Drug Administration (FDA): levalbuterol and formoterol. Both of these drugs are similar to standard asthma bronchodilator drugs but offer theoretical advantages in terms of fewer side effects. There are also newer devices to deliver these medications into the lungs: breath actuated nebulizers (BANs) and non-static chambers (Aerochamber-max) that can be used with metered dose inhalers (MDIs or "puffers"). The purpose of this study is to deliver these new medications using several different devices and measuring lung function, heart rate, and sensations of breathlessness.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 23, 2014
Enrollment StartJul 1, 2007
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 12.0 years ago

Interventions

levalbuteroldrug

0.5 ml. levalbuterol

salinedrug

0.5ml saline

levalbuterol MDIother

breath actuated nebulizerdevice

aerochamber maxdevice

ipratropriumdrug